Once-nightly regular-release lithium cuts kidney risk, maintains bipolar control, improves adherence, and guides safer serum levels.
News
Why psychiatrists must talk about sex: sexual dysfunction can exacerbate comorbid psychiatric disorders and contribute to medication nonadherence.
AbbVie’s short-acting psychedelic bretisilocin shows rapid MADRS drops in phase 2a MDD trials, hinting at scalable, supervised depression care.
Explore the brain’s 5 monoamines—beyond serotonin and dopamine—revealing histamine, melatonin, and trace amines shaping sleep, appetite, and mood.
Explore 2026’s fast-moving psych med pipeline: new Alzheimer agitation option, potential novel ADHD therapy, and promising psilocybin for depression.
Lawsuits, research, and clinicians clash over youth screen addiction—learn more about how problematic social platform use evades diagnosis and how we can curb harm.
Phase 2 trial shows elunetirom rapidly eases bipolar depression symptoms with strong response, good tolerability, and FDA Fast Track momentum.
Discover an objective suicide risk assessment for patients denying ideation, using Suicide Crisis Syndrome and staged warning signs to guide earlier intervention.
Blood exosomal microRNA markers reveal oxidative-stress subtypes, predict psychosis conversion, and guide early, targeted treatments like MitoQ.
New DOE RISE rule cuts federal loan limits for graduate nursing, PAs, and social work—threatening workforce diversity and care access.
FDA issues CRL for CTx-1301 in ADHD.
Explore Pride Month insights on LGBTQ+ and other minoritized patients—social determinants, research, practice tips, and case studies for clinicians, in our June theme.
Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.
Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.
DSM’s future adds biomarkers and context, yet validity remains unresolved—are diagnoses real? Critics urge an evidence-based overhaul.
Check out the pipeline updates from May!
Real-world claims show opioids remain common in fibromyalgia despite guidance, highlighting safety concerns and interest in FDA-approved non-opioid option Tonmya.
Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from 2 sessions.
FDA clears Modius Spero headset, a noninvasive at-home neuromodulation therapy that eases PTSD symptoms, with veterans first to access via VA.
Explore how integrated psychotherapy—CBTp, family support, and humane alliance—reduces relapse and restores meaning beyond medication in schizophrenia.
New Surgeon General advisory warns of youth screen and social media harms, urging families, schools, and clinicians to act with the 5 Ds.
Learn how to spot bipolar mixed features, avoid antidepressant pitfalls, and choose evidence-based antipsychotics.
In this CME article, explore a 4-stage framework that detects suicide risk without ideation disclosure, guiding clinicians to spot crisis signs and act fast.
Synendos launches a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety symptoms with improved safety and adherence.
Four fathers share real-time signs of suicide crisis syndrome—insomnia, agitation, withdrawal—showing why standard screening misses imminent danger.
Real-world registry data reveals young adults with mood disorders face high TD burden yet low diagnosis rates, spotlighting urgent screening gaps.
Why schizophrenia shortens life: smoking, metabolic risks, and care gaps drive a 15-year mortality loss—and clinicians can help close it.
GLP-1 drugs like semaglutide may curb alcohol and opioid cravings, as trials expand, combos emerge, and interaction risks surface.
Study ties higher schizophrenia rates in Black Americans to neighborhood vulnerability, spotlighting faster early-psychosis care and social supports.
Phase 2 MINDFuL data show XPro trends toward cognitive and biomarker gains in inflammation-defined mild Alzheimer disease, with no ARIA, guiding phase 3 plans.